Latest News

1. 22 June
   

PolyTherics TheraPEG™ Patent Allowed in Europe

1. 12 May
   

PolyTherics and Celtic Pharma enter Product Licence Agreement for novel optimised biopharmaceuticals

1. 8 April
   

PolyTherics to present recent developments in improving antibody fragments for therapeutic use at PEGS Protein Engineering Summit, Boston

1. ➡ More News
   

Click to view or download brochure

on TheraPEG™ technology

1. ➡ More Downloads

PolyTherics is a company dedicated to using biomedical polymers to optimise pharmaceuticals, in particular biopharmaceuticals, for the treatment and cure of the world’s most important diseases.

PolyTherics’ most advanced programmes are designed to exploit TheraPEG™ technology, an innovative, patent protected approach to the PEGylation of therapeutic proteins and antibody fragments. Through the targeted attachment of PEG via naturally occurring disulfide bonds within proteins, biochemical and biophysical properties can be altered without compromising biological activity.

Beyond targeted PEGylation, PolyTherics has developed proprietary polymer-based technologies for application to both small molecules and large proteins, to create a broad portfolio of improved medicines.